Pharma Business - October 5, 2015
Karolinska Development divests its holding in XSpray
Karolinska Development divests its holding in XSpray Microparticles AB to an investment consortium led by Östersjöstiftelsen and Recipharm Venture Fund Karolinska Development AB announces that it divests its entire shareholding in the drug delivery company XSpray Microparticles AB to a consortium led by The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Recipharm Venture […]
Profiles in Business - September 10, 2015
Jim Van heusden, CEO of Karolinska Development
Nordic Life Science Magazine had an exclusive interview with Jim Van heusden, the new CEO of Karolinska Development.
In a new job - October 15, 2014
New CEO for Karolinska Development
Bruno Lucidi has been appointed permanent CEO of Karolinska Development. Bruno Lucidi has previously been founding CEO of Idenix and Chairman of Pharmasset. He has also held senior positions within Bristol-Myers Squibb, Johnson & Johnson and at GlaxoSmithKline. Since September 8, 2014, Bruno Lucidi is CEO of the Karolinska Development’s wholly owned subsidiary KDev Oncology as well […]
In a new job - September 30, 2014
Karolinska Development CEO leaves post
Karolinska Development has announced that CEO Torbjörn Bjerke leaves the company. Bjerke will be replaced by Klaus Wilgenbus until a new permanent CEO has been appointed. Torbjörn Bjerke leaves his position as CEO on September 30, 2014, and Klaus Wilgenbus steps down from his Board position in Karolinska Development and assumes his new duties with immediate effect. Karolinska Development states […]
Clinical Trials - March 14, 2014
Aprea initiates new study
Karolinska Development’s portfolio company Aprea is to evaluate its drug candidate for the treatment of ovarian cancer in a new British study. It is a phase 1b/II study on the pharmaceutical project APR-246, reports Life Science Sweden. The drug candidate is part of a new type of potential cancer drugs that lead the cancer cells […]
Agreement - February 24, 2014
Dilafor in new license agreement
Dilafor AB, part of Karolinska Development’s portfolio of companies, has signed an agreement with Hong Kong-based biopharmaceutical firm. According to the agreement, Dilafor grants to Lee’s Pharmaceutical the right to manufacture, develop and commercialize tafoxiparin for obstetrics and gynecological indications in China, Hong Kong, Macau and Taiwan. Pursuant to the terms of the agreement, Dilafor and Lee’s […]
